Cargando…

Cisplatin Promotes the Efficacy of Immune Checkpoint Inhibitor Therapy by Inducing Ferroptosis and Activating Neutrophils

The combination of immunotherapy with platinum-based chemotherapy has become the first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) with negative driver gene mutations. However, finding an ideal chemotherapeutic regimen for immunotherapy and exploring the underlying m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Ziwei, Zhao, Yiming, Chen, Si, Cui, Guohui, Fu, Wenkui, Li, Shouying, Lin, Xiaorong, Hu, Hai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240830/ https://www.ncbi.nlm.nih.gov/pubmed/35784745 http://dx.doi.org/10.3389/fphar.2022.870178

Ejemplares similares

Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer
por: Yang, Rui, et al.
Publicado: (2022)

Identification of Key Genes and FUNCTIONAL Pathway in Radioresistance of Non-Small Cell Lung Cancer
por: Li, Shouying, et al.
Publicado: (2022)

Potential role of gut microbes in the efficacy and toxicity of immune checkpoints inhibitors
por: Ma, Jingxin, et al.
Publicado: (2023)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
por: Chen, Xi, et al.
Publicado: (2022)

Clinical Insights Into Novel Immune Checkpoint Inhibitors
por: Lee, Jii Bum, et al.
Publicado: (2021)

Resistance to immune checkpoint inhibitors in gastric cancer
por: Liu, Kai, et al.
Publicado: (2023)

Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment
por: Zhao, Jing, et al.
Publicado: (2019)

Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials
por: Yu, Jiahui, et al.
Publicado: (2023)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

VPA improves ferroptosis in tubular epithelial cells after cisplatin-induced acute kidney injury
por: Li, Yan, et al.
Publicado: (2023)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Drug therapy for myocarditis induced by immune checkpoint inhibitors
por: Wu, Yihao, et al.
Publicado: (2023)

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
por: Calvo, Roser
Publicado: (2019)

How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy
por: Spallarossa, Paolo, et al.
Publicado: (2020)

Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
por: Albarrán, Víctor, et al.
Publicado: (2022)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
por: Li, Ji, et al.
Publicado: (2022)

Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future
por: Zhang, Zeng, et al.
Publicado: (2022)

The influence of baseline characteristics on the efficacy of immune checkpoint inhibitors for advanced lung cancer: A systematic review and meta-analysis
por: Xiao, Qionghua, et al.
Publicado: (2022)

Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis
por: Liu, Xiangxing, et al.
Publicado: (2022)

Efficacy and safety of immune checkpoint inhibitors and targeted therapies in resected melanoma: a systematic review and network meta-analysis
por: Sheng, Feng, et al.
Publicado: (2023)

Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis
por: Liu, Zijing, et al.
Publicado: (2023)

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives
por: Liu, Zherui, et al.
Publicado: (2023)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022)

Comprehensive analysis of ferroptosis-related genes in immune infiltration and prognosis in multiple myeloma
por: Wang, Quanqiang, et al.
Publicado: (2023)

The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis
por: Ning, Biao, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
por: Qian, Xiaoyu, et al.
Publicado: (2022)

A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Liao, Dan, et al.
Publicado: (2019)

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
por: Niu, Yuchun, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management
por: Wang, Haiyang, et al.
Publicado: (2019)

Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids
por: Han, Yi, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
por: Ruggiero, Rosanna, et al.
Publicado: (2020)

The Organelle-Specific Regulations and Epigenetic Regulators in Ferroptosis
por: Zhang, Yixuan, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
por: Zhou, Yu-Wen, et al.
Publicado: (2019)

Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review
por: Gao, Ling, et al.
Publicado: (2019)

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Zou, Xue-lin, et al.
Publicado: (2021)

The correlation between probiotic use and outcomes of cancer patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2022)

Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis
por: Zhang, Tian, et al.
Publicado: (2022)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Wen, Yang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q0a4ec7blga76l5odnbglli36r